Antisense c-myc retroviral vector suppresses established human prostate cancer

Human Gene Therapy
M S SteinerJ T Holt

Abstract

Prostate cancer eventually becomes androgen resistant, resumes growth, and kills the patient. Characterization of genetic events that lead to androgen refractory prostatic neoplasia has revealed the frequent overexpression of c-myc and uncontrolled prostate cancer proliferation. A novel strategy to combat advanced prostate cancer utilized a replication incompetent retrovirus that contained the mouse mammary tumor virus (MMTV) promoter within the retroviral vector to allow transcription of antisense c-myc gene within target prostate tumor cells. The transduction of cultured DU145 cells by XM6:MMTV-antisense c-myc RNA retrovirus did not affect cell proliferation in culture, yet a single direct injection of MMTV-antisense c-myc viral media into established DU145 tumors in nude mice produced a 94.5% reduction in tumor size compared to tumors treated with control virus MTMV sense fos and untreated tumor by 70 days. Two animals in the antisense c-myc-treated group had complete regression of their tumors. Histopathological examination of the tumors revealed that MMTV-antisense c-myc-transduced DU145 tumors had increased tumor cell differentiation, decreased invasion, and a marked stromal response. The mechanism for the antitumor effec...Continue Reading

References

Oct 8, 1992·Nature·R P BissonnetteD R Green
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·K Yokoyama, F Imamoto
Oct 30, 1985·Biochemical and Biophysical Research Communications·A W RijndersJ Trapman
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·J J RyanM F Clarke
Sep 7, 1994·Journal of the National Cancer Institute·B W Stewart
Jan 1, 1993·Methods in Enzymology·A D MillerC M Lynch
Feb 1, 1993·Cancer·D M Peehl
Feb 1, 1993·Current Opinion in Genetics & Development·G I Evan, T D Littlewood
Apr 1, 1993·Molecular and Cellular Biology·A J WagnerN Hay
Jan 1, 1997·CA: a Cancer Journal for Clinicians·S L ParkerP A Wingo
Mar 1, 1997·Urologic Oncology·Y Z Wang, Y C Wong

❮ Previous
Next ❯

Citations

Nov 24, 1999·Genes, Chromosomes & Cancer·R E ReiterR B Jenkins
Jun 29, 2000·Medical Oncology·S N PentyalaS A Khan
Aug 8, 2001·Current Oncology Reports·J R GingrichM S Steiner
Jul 26, 2002·Tropical Doctor·R Krishna Rao
Dec 4, 2008·Asian Journal of Andrology·Sachin AgrawalWilliam D Dunsmuir
Aug 5, 2010·Molecular Cancer Therapeutics·Nagathihalli S NagarajNipun B Merchant
Dec 24, 2005·Expert Opinion on Drug Delivery·Sergey A Kaliberov, Donald J Buchsbaum
Dec 1, 2001·Expert Opinion on Biological Therapy·T C ThompsonD Kadmon
Jul 10, 2001·The Journal of Investigative Dermatology·H HegyesiZ Darvas
Apr 29, 2008·Cancer Letters·Chulso MoonSaechul Kim
Apr 25, 2006·The Urologic Clinics of North America·Pratik DesaiThomas A Gardner
Aug 4, 2004·The Lancet Oncology·Ruth FoleyDonal Hollywood
Sep 19, 2000·The Journal of Urology·M S Steiner, J R Gingrich
Jun 11, 1999·The Urologic Clinics of North America·G S PalapattuA S Belldegrun
Feb 27, 2001·FEBS Letters·S NasiL Soucek
Oct 7, 2003·Oncogene·Annamaria BiroccioGabriella Zupi
Sep 8, 2001·The Journal of Urology·K J HarringtonR G Vile
Jul 13, 2002·Expert Review of Anticancer Therapy·Yehoshua GdorTimothy C Thompson
Sep 15, 2004·Prostate Cancer and Prostatic Diseases·P PatelN James
Mar 11, 2004·BJU International·D Mazhar, J Waxman
Jun 27, 2002·Current Urology Reports·J R GingrichM S Steiner
May 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hector BiliranJoshua D Liao

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.